4-(O-methylhydroxylamino)-3-(N-p-chlorophenylcarbamoyl)-5,6,7,8-tetrahydroquinoline | 102200-93-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(O-methylhydroxylamino)-3-(N-p-chlorophenylcarbamoyl)-5,6,7,8-tetrahydroquinoline
• 英文别名: N-(4-chlorophenyl)-4-(methoxyamino)-5,6,7,8-tetrahydroquinoline-3-carboxamide
• CAS: 102200-93-1
• 化学式: C₁₇H₁₈ClN₃O₂
• 分子量: 331.802
• InChiKey: IDICWPHFHGLXPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  63.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(O-methylhydroxylamino)-3-(N-p-chlorophenylcarbamoyl)-5,6,7,8-tetrahydroquinoline 生成 2-p-chlorophenyl-2,3,6,7,8,9-hexahydropyrazolo[4,3-c]quinolin-3(5H)-one hydrochloride
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  4-chloro-3-(N-p-chlorophenylcarbamoyl)-5,6,7,8-tetrahydroquinoline 、 甲氧基胺盐酸盐 生成 4-(O-methylhydroxylamino)-3-(N-p-chlorophenylcarbamoyl)-5,6,7,8-tetrahydroquinoline
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating
  申请人：Ciba-Geigy Corporation

  公开号：US04647566A1

  公开（公告）日：1987-03-03

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物 ##STR1## 其中A代表可选取代的饱和二价基团，与其相连的两个碳原子一起代表从可选取代的融合的环戊烯、环己烯、环庚烯、二氢噻吩、二氢硫吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吡喃、二氢吡咯烷、四氢吡啶和四氢氮杂七环中选择的融合的5、6或7元环；R.sub.1代表低级烷基、苯基或被低级烷基、低级烷氧基、卤素或三氟甲基单取代或双取代的苯基；或R.sub.1代表从可选取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基中选择的芳香族杂环基；R.sub.2、R.sub.3、R.sub.3 '为氢或低级烷基；以及药学上可接受的盐；用于治疗神经系统疾病的苯二氮平受体调节剂。还公开了制药组合物、制备方法和某些用作苯二氮平受体调节剂的中间体。
• Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one
  申请人：Ciba-Geigy Corporation

  公开号：US04740512A1

  公开（公告）日：1988-04-26

  Compounds of the formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  公式IA或IB的化合物##STR1##其中，A代表一个可选的取代饱和双价基团，它与它附着的两个碳原子一起代表从可选的取代融合的环戊烯，环己烯，环庚烯，二氢噻吩，二氢噻吩吡喃，四氢噻吩，二氢呋喃，二氢吡喃，四氢氧吡喃，二氢吡咯烷，四氢吡啶和四氢氮杂环庚烷中选择的一个融合的5、6或7成员环；R.sub.1代表较低的烷基，苯基或由较低的烷基，较低的烷氧基，卤素或三氟甲基单取代或双取代的苯基；或R.sub.1代表选自例如可选取代的吡啶基，喹啉基，异喹啉基，嘧啶基和噻唑基的芳香杂环基；R.sub.2，R.sub.3，R.sub.3'是氢或较低的烷基；以及药学上可接受的盐；用作苯二氮平受体调节剂，用于治疗神经系统疾病。还公开了药物组合物，制备方法和某些中间体，这些中间体有用作苯二氮平受体调节剂的作用。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US04814450A1

  公开（公告）日：1989-03-21

  Compounds of the formula formula IA or IB ##STR1## wherein A represent an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.4 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物##STR1##其中A代表一个可以选择性取代的饱和二价基团，与其相连的两个碳原子共同代表一种选择自可选择性取代的融合的5-,6-或7-成员碳环或杂环，所述环选自可选择性取代的融合的环戊烯基，环己烯基，环庚烯基，二氢噻吩基，二氢噻吩并吡喃基，四氢噻环并吡喃基，二氢呋喃基，二氢吡喃基，四氢氧环并吡喃基，二氢吡咯基，四氢吡啶基和四氢氮杂环并吡喃基；R.sub.1代表较低的烷基，苯基，或被较低的烷基，较低的烷氧基，卤素或三氟甲基单取代或双取代的苯基；或R.sub.1代表选自例如可选择性取代的吡啶基，喹啉基，异喹啉基，嘧啶基和噻唑基的芳香族杂环基；R.sub.2，R.sub.3，R.sub.4'为氢或较低的烷基；以及药学上可接受的盐；用作苯二氮平受体调节剂，用于治疗神经系统疾病。还公开了制药组合物，制备方法和某些中间体，这些中间体用作苯二氮平受体调节剂。
• Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine
  申请人：Ciba-Geigy Corporation

  公开号：US04602014A1

  公开（公告）日：1986-07-22

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物##STR1##其中A代表一个可选的取代饱和双价基团，它与它附着的两个碳原子一起代表选择的可选取代的融合5-，6-或7-成员的碳环或杂环，所述环选自可选取代的融合环戊烯，环己烯，环庚烯，二氢噻吩，二氢噻吩吡喃，四氢噻吩，二氢呋喃，二氢吡喃，四氢氧杂噻吩，二氢吡咯烷，四氢吡啶和四氢氮杂七环；R.sub.1代表低级烷基，苯基或低级烷基，低级烷氧基，卤素或三氟甲基取代的苯基单取代或双取代；或R.sub.1代表从可选取代的吡啶基，喹啉基，异喹啉基，嘧啶基和噻唑基等中选择的芳香族杂环基；R.sub.2，R.sub.3，R.sub.3 '代表氢或低级烷基；以及药学上可接受的盐；用于治疗神经系统疾病的苯二氮平受体调节剂。还公开了制药组合物，制备方法以及用作苯二氮平受体调节剂的某些中间体。
• ——
  作者：YOKOYAMA NAOKATA

  DOI：——

  日期：——